• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Capricor Therapeutics Inc.

    2/17/26 4:11:37 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Capricor Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    14070B309

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    14070B309


    1Names of Reporting Persons

    Highbridge Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,200,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,200,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,200,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.3 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  The 1,200,000 shares of Common Stock (as defined in Item 2(a)) are issuable upon exercise of warrants reported herein.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Capricor Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    10865 Road to the Cure, Suite 150, San Diego, CA 92121
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Capricor Therapeutics, Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of the Reporting Person is 390 Madison Avenue, 28th Floor, New York, NY 10017.
    (c)Citizenship:

    Highbridge is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    14070B309
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 51,716,975 shares of Common Stock outstanding as of December 5, 2025, as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on December 5, 2025, after giving effect to the completion of the offering, as described therein, and assumes the exercise of the warrants held by the Highbridge Funds.
    (b)Percent of class:

    2.3%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Highbridge Capital Management, LLC
     
    Signature:/s/ Kirk Rule
    Name/Title:Kirk Rule, Executive Director
    Date:02/17/2026
    Get the next $CAPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAPR

    DatePrice TargetRatingAnalyst
    6/30/2025$20.00Buy
    Alliance Global Partners
    6/26/2025$21.00Buy
    B. Riley Securities
    5/20/2025$31.00Buy
    Roth Capital
    10/21/2024$35.00Overweight
    Piper Sandler
    5/17/2024$14.00Outperform
    Oppenheimer
    1/5/2024$8.00Overweight
    Cantor Fitzgerald
    10/26/2022$15.00Buy
    Ladenburg Thalmann
    1/31/2022$14.00 → $18.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CAPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Nippon Shinyaku Co Ltd bought $14,999,998 worth of shares (2,798,507 units at $5.36), increasing direct ownership by 65% to 7,090,351 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    9/24/24 4:01:08 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Musket David B bought $1,128 worth of shares (410 units at $2.75), increasing direct ownership by 1% to 31,536 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    10/13/23 1:59:57 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Collier Earl M Jr bought $28,300 worth of shares (10,000 units at $2.83), increasing direct ownership by 59% to 26,856 units (SEC Form 4)

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    10/12/23 9:15:07 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Capricor Therapeutics Inc.

    SCHEDULE 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    2/17/26 4:11:37 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Capricor Therapeutics Inc.

    S-8 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

    1/30/26 5:01:12 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Capricor Therapeutics Inc.

    424B5 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

    12/5/25 5:29:42 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Marban Linda

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    1/7/26 4:45:28 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kelliher Mike

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    1/7/26 4:45:21 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF FINANCIAL OFFICER Bergmann Anthony

    4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)

    1/7/26 4:45:26 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data

    FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today provided a regulatory update regarding its Biologics License Application (BLA) for Deramiocel, the Company's investigational first-in-class cell therapy for the treatment of Duchenne muscular dystrophy (DMD). As previously disclosed, the Company provided topline results from its Phase 3 HOPE-3 clinic

    1/20/26 9:15:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

    – Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor's Phase 3 HOPE-3 trial evaluating Deramiocel, the Company's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). The webinar will provide patients and families with an overview of the HOPE-3 results and how the findings inform ongoing regulatory discussions, including

    12/16/25 4:05:00 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

    SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about December 8, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expecte

    12/5/25 6:15:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Capricor Therapeutics with a new price target

    Alliance Global Partners initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $20.00

    6/30/25 7:58:51 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Capricor Therapeutics with a new price target

    B. Riley Securities initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $21.00

    6/26/25 8:09:16 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Capricor Therapeutics with a new price target

    Roth Capital initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $31.00

    5/20/25 8:11:35 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Leadership Updates

    Live Leadership Updates

    View All

    Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

    SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors. "Michael is an outstanding addition to Capricor's leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities," said Linda

    5/13/25 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

    SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets today, July 1, 2024. "We are thrilled to be joining the Russell 2000® Index, a testament to our Company's progress across our pipeline marked by significant advancements in our lead program for the treatment of Duchenne muscular dystrophy," said Linda Marbán, Ph.D., Capricor's chief executive officer. "This milestone reflects Ca

    7/1/24 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

    SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately. Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry. "It is a pleasure to welcome Mike to our Board of Directors, who has an extraor

    9/6/23 9:00:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Financials

    Live finance-specific insights

    View All

    Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

    Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat Duchenne cardiomyopathy, the leading cause of mortality in DuchenneDeramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experienceCompany plans to submit i

    12/3/25 7:20:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3 study, the Company expects to resubmit its BLA, leveraging the data in support of its application for approvalCommercial launch preparations underway to support potential approval and market introduction of Deramiocel in 2026NIAID-sponsored Phase 1 clinical trial underway with StealthX™ exosome-based vaccine; initial topline data currently expected in the first quarter of 2026, subject to completion by NIAIDCash balance of approximately $99 million expected to support planned oper

    11/10/25 4:01:00 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

    SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2025, after the market close on Monday, November 10, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on the same day. Title:Capricor Therapeutics Third Quarter 2025 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Monday, November 10, 2025Time:4:30 p.m. ETCall Details:Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference

    10/31/25 9:15:00 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

    SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    11/8/24 9:00:23 AM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

    SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    9/24/24 4:03:22 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Capricor Therapeutics Inc.

    SC 13G/A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Subject)

    8/23/24 4:01:31 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care